Christoph Röllig, MD, MSc, is a Senior Physician and Head of Clinical Studies at the University Hospital Carl Gustav Carus, Dresden, Germany. He carried out his medical training in Berlin, before completing a master’s degree in public health in London. Dr Röllig has a prominent role in The Study Alliance Leukemia (SAL) – a cooperative study platform made up of nearly 60 centers – as a steering committee member and head of the SAL study center. His work has been published in several high-profile journals and he has presented at national and international meetings.
Speaking on the treatment of AML and myeloma
Dr Röllig is an expert in acute myeloid leukemia (AML) and multiple myeloma and conducts translational research in these fields. He is frequently involved in the running and conduction of early- and late-phase clinical trials in AML and myeloma. Dr Röllig is currently directing a large multicenter study to establish a clinical AML registry and biomaterial database across 40 sites in Germany.